To hear about similar clinical trials, please enter your email below
Trial Title:
A Symptom Management Application for Children at the Early Stage of Cancer Survivorship and Their Caregivers
NCT ID:
NCT05748210
Condition:
Oncology
Survivorship
Conditions: Official terms:
Neoplasms
Conditions: Keywords:
symptom management
cancer
children
caregiver
mobile health
Study type:
Interventional
Study phase:
N/A
Overall status:
Not yet recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Supportive Care
Masking:
Single (Outcomes Assessor)
Intervention:
Intervention type:
Other
Intervention name:
Symptom management mobile health application with personalised support
Description:
Child-caregiver dyads in the intervention group will use the mHealth app for 12 weeks
with personalised nurse support via interactive communication technologies. The design of
the app will be guided by the theory of unpleasant symptoms.
The app will comprise several interactive elements to provide children and their
caregivers with real-time symptom management support. Comprehensive educational materials
regarding cancer and its treatment side effects, including possible symptoms, functional
limitations, and psychological responses, will be provided in the app for the children
and their caregivers to gain a thorough understanding of the potential symptom burden
that they may experience.
Arm group label:
Intervention group
Intervention type:
Other
Intervention name:
Wait-list Symptom management mobile health application with personalised support
Description:
To ensure the equity of access to a potentially desirable and effective intervention
(i.e., mHeath app for symptom management), participants in the wait-list control group
will be invited to receive the same intervention as participants in the intervention
group after the completion of all assessments on a voluntary basis.
Arm group label:
Wait-list control group
Summary:
The goal of this randomized controlled trial is to examine the efficacy of the mHealth
app in improving symptoms experienced by children in the early stage of cancer
survivorship, including physical function, anxiety, depressive symptoms, fatigue, peer
relationships, and pain interference, and at improving the quality of life (QoL) of the
children's primary caregivers
The main question it aims to answer is whether survivors who receive the symptom
management mHealth app intervention will report improved symptoms, i.e., improved
physical function; lower levels of anxiety, depressive symptoms, and fatigue; better peer
relationships; and lower pain interference 3 months after starting the intervention.
Additionally, we hypothesized that the primary caregivers (either the mother or father)
would report an improved QoL 3 months after starting the intervention.
Participants in the intervention group will use the mHealth app for 12 weeks with
personalised nurse support via interactive communication technologies. They are required
to complete questionnaires at baseline (during medical follow-up), 1, 2, and 3 months
(via electronic-based systems in the mobile app) Besides, semi-structured interviews and
will be conducted to examine the usability, feasibility, and acceptability of the
intervention.
Detailed description:
In Hong Kong, the incidence of paediatric cancer has been increasing in the past few
years, from 180 new cancer cases in 2017 to 196 cases in 2019 [1]. The average 5-year
survival rate for paediatric cancer patients is approximately 85% due to recent advances
in cancer treatments [2]. The success of these treatments has resulted in a rapid growth
in the population of paediatric cancer survivors globally. This population now has an
average lifespan of 72 years [2]. Despite the improved survival rate, the high toxicity
and low specificity of cancer treatment given at an early age induce a myriad of
deleterious late effects that have a detrimental impact on survivors' physical and
psychosocial well-being [3-5]. Therefore, children who have completed cancer treatment
require ongoing monitoring for cancer progression and survivorship care as early as
possible to manage the symptoms induced by the invasive treatment. Symptom management in
paediatric oncology nursing is becoming increasingly important due to the complex
treatment modalities. The benefits of effective symptom management, particularly
improvements in physical functioning and reduced psychological distress, are exponential
for children being treated for cancer and their caregivers throughout the cancer
trajectory.
Paediatric oncology patients receive close monitoring of their somatic symptoms during
their hospital stay, but there is a paucity of symptom management for children who have
completed treatment and are at the early stage of survivorship. During the transition
from hospital stay to home care, children and their caregivers may experience significant
psychological distress due to their concerns about the child's health and uncertainties
about coping with the potential symptom burden or cancer recurrence. During the first
year after completing cancer treatment, many side effects related to the cancer or its
treatment may persist, and other late effects may also develop [3]. The unmet needs for
symptom monitoring and management for paediatric cancer survivors, particularly those in
the early stage of survivorship, warrant immediate attention from healthcare
professionals. It is imperative for healthcare professionals to engage in the rigorous
planning, development, and implementation of appropriate interventions to support symptom
management for children in the early stage of cancer survivorship and their caregivers.
These interventions should be implemented at discharge to manage patient-reported
symptoms and improve the children's QoL and survival rate.
Given the high utilisation of mobile technologies, integrating mobile technologies into
current cancer survivorship care may be a promising and flexible approach for symptom
management for children in the early stage of cancer survivorship and their caregivers.
Digital health interventions have been shown to be effective at improving
patient-reported outcomes in various patient populations, but there is a lack of such an
intervention for paediatric cancer survivors and their caregivers to ameliorate their
symptom burden in their local contexts (e.g., at home). The proposed study aims to
develop a symptom management mHealth app to support children in the early stage of cancer
survivorship and their caregivers and to evaluate its usability, feasibility,
acceptability, and efficacy.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
Chinese paediatric cancer survivors will be included if they
- are aged 9 to 16 years,
- are able to read Chinese and communicate in Chinese,
- have completed active cancer treatment (within the previous 2 years), as early
symptom management support is crucial to reduce the symptom burden in survivors and
their caregivers throughout their survivorship, and
- have a smartphone or tablet and are willing to install the mHealth app.
The primary caregiver of the paediatric cancer survivors (either the mother or father)
- are able to read Chinese and communicate in Chinese, and
- have a smartphone or tablet and are willing to install the mHealth app with their
children surviving cancer.
Exclusion Criteria:
Chinese paediatric cancer survivors will be excluded if they
- have cognitive impairments or psychiatric illnesses
- are currently participating in other symptom management studies, or
- have evidence of secondary malignancy or recurrence
The primary caregivers of the paediatric cancer survivors (either the mother or father)
will be excluded if they have cognitive impairments or psychiatric illnesses.
Gender:
All
Minimum age:
9 Years
Maximum age:
16 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
The Chinese University of Hong Kong
Address:
City:
Hong Kong
Country:
Hong Kong
Contact:
Last name:
Ankie Tan Cheung, PhD
Phone:
852 39430515
Email:
ankiecheung@cuhk.edu.hk
Contact backup:
Last name:
William Ho Cheung Li, PhD
Phone:
852 39430889
Email:
williamli@cuhk.edu.hk
Start date:
September 1, 2024
Completion date:
February 28, 2025
Lead sponsor:
Agency:
Chinese University of Hong Kong
Agency class:
Other
Source:
Chinese University of Hong Kong
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05748210